close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by LumiraDx Inc

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening Hub
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Reports Second Quarter 2023 Results
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV Tests
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Reports First Quarter 2023 Results
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Announces Strategic Refocus and Cost Restructuring Program
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx to Present at Raymond James Institutional Investors Conference
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx Reports Third Quarter 2022 Results
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
From LumiraDx Inc
Via GlobeNewswire
Tickers LMDX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today